4D Molecular Therapeutics (FDMT) Property, Plant & Equipment (Net) Growth (1y) (2020 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Property, Plant & Equipment (Net) Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 24.71% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.77% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -99.85% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -5.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.70% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 10.87% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 19.14% |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | -29.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.28% |
| Mar 31, 2026 | -27.52% |
| Dec 31, 2025 | -23.89% |
| Sep 30, 2025 | -18.69% |
| Jun 30, 2025 | -6.69% |
| Mar 31, 2025 | -3.69% |
| Dec 31, 2024 | -2.94% |
| Sep 30, 2024 | -4.20% |
| Jun 30, 2024 | -11.90% |
| Mar 31, 2024 | -9.95% |
| Dec 31, 2023 | -9.59% |
| Sep 30, 2023 | -5.96% |
| Jun 30, 2023 | 0.94% |
| Mar 31, 2023 | 17.11% |
| Dec 31, 2022 | 54.69% |
| Sep 30, 2022 | 150.90% |
| Jun 30, 2022 | 278.08% |
| Mar 31, 2022 | 268.31% |
| Dec 31, 2021 | 183.68% |
| Dec 31, 2020 | 0.48% |